New in situ mouse model to quantify alveolar epithelial fluid clearance.
Because the availability of transgenic mice makes it possible to examine the contribution of single genes to in vivo function, we developed a simple in situ mouse model that can be used to quantify isosmolar alveolar epithelial fluid clearance (AFC). Mice were killed, a tracheostomy was done, and then a test solution of a 5% isosmolar albumin solution with 0.1 micro Ci of 125I-labeled albumin was instilled via the trachea into the distal air spaces of both lungs. After instillation, the lungs were inflated to 7 cmH2O with 100% O2 and maintained at 37 degrees C by placing the animals under an infrared lamp. AFC was measured by the progressive increase in concentration of labeled and unlabeled protein over 1 h. The results indicated the following. 1) Basal, unstimulated AFC in mouse lungs was significantly faster than in ex vivo rat lungs (27 +/- 5% in in situ mice vs. 11 +/- 3% in ex vivo rat lungs; P < 0.05). 2) Comparison of equivalent doses (10(-4) M) of beta-adrenergic agonist (isoproterenol) and beta2-adrenergic agonists (terbutaline and salmeterol) indicated that stimulated clearance occurred only in presence of isoproterenol. 3) Because atenolol, a specific beta1-antagonist, abolished the effect of isoproterenol, the beta-adrenergic stimulation appears to be mediated by beta1-receptors. The rate of AFC in nonperfused mouse lungs was significantly faster than in prior studies of nonperfused lungs in rats and sheep. Interestingly, the stimulated clearance rate in mice was similar to the fast rates of AFC that we recently reported in patients recovering from hydrostatic pulmonary edema. This in situ model is a unique experimental preparation that can be readily used to quantify isosmolar epithelial fluid clearance in mice.
Garat
C
C
Cardiovascular Research Institute, University of California, San Francisco 94143-0130, USA.
Carter
E P
EP
Matthay
M A
MA
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D001262:Atenolol / Q000494:pharmacology; D018893:Bronchoalveolar Lavage; D004195:Disease Models, Animal; D005110:Extracellular Space / Q000502:physiology*; D007457:Iodine Radioisotopes / Q000378:metabolism; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010477:Perfusion / Q000379:methods; D011650:Pulmonary Alveoli / Q000502:physiology*; D011654:Pulmonary Edema / Q000503:physiopathology; D012709:Serum Albumin / Q000378:metabolism; D026941:Sodium Channel Blockers; D013726:Terbutaline / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D007457:Iodine Radioisotopes; D012709:Serum Albumin; D026941:Sodium Channel Blockers; D001262:Atenolol; D000584:Amiloride; D007545:Isoproterenol; D013726:Terbutaline